Saturday 17 October 2026
Export PPCB’s income statement to Excel — free account
Propanc Biopharma Inc
PPCB Healthcare Biotechnology
In the quarter to June 2026, EPS fell 99.6%, free cash flow fell 1,637.4% and total debt fell 21.4%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow PPCB
Propanc Biopharma Inc (PPCB) P/E ratio
Propanc Biopharma Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 26.5× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 26.5×
Ten-year median
0.0×
Current reading's percentile
84
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IOBTQ IO Biotech, Inc. compare | n/m |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| ERNA Ernexa Therapeutics Inc. compare | n/m |
| PPCB Propanc Biopharma Inc | n/m |
| KALA KALA BIO, Inc. compare | n/m |
| LIPO Lipella Pharmaceuticals Inc. compare | n/m |
| UNBX UNITY Biotechnology, Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)